Lakefront Biotherapeutics NV has repurchased 38,537 of its own shares between June 9, 2026 and June 12, 2026, as part of a repurchase program announced on June 9, 2026. The company acquired the shares on Euronext (ENXT) at an average price of €24.7764, spending a total of €954,808.90. This transaction reduces the number of shares in circulation, potentially increasing earnings per share for remaining shareholders.

Repurchase Details

The buyback activity was conducted over three trading days, with the highest volume recorded on June 10, 2026. The price paid per share ranged from a low of €24.3600 to a high of €25.0800. The following table details the daily breakdown of the repurchases:

Current Holdings

As of the market close on June 12, 2026, Lakefront Biotherapeutics NV holds 38,537 of its own ordinary shares. The company is listed on Euronext and NASDAQ under the ticker symbol LKFT. Lakefront Biotherapeutics (formerly known as Galapagos) is a biotechnology company focused on immunology and inflammation, with a clinical-stage portfolio anchored by gamgertamig, a potential first-in-class BCMAxCD3 T-cell engager for autoimmune diseases.

Lakefront Biotherapeutics NV appointed Eric Hedrick, MD, as Chief Medical Officer to strengthen its leadership team and advance its R&D pipeline following the acquisition of Ouro Medicines' operational assets. Hedrick, who previously served as clinical evaluation lead for new pipeline opportunities, will report to Henry Gosebruch, CEO, and join the company's Management Committee. The appointment, announced on June 8, 2026, aligns with Lakefront's strategic transformation and focus on oncology and immunology & inflammation programs.

Hedrick brings over 25 years of experience in developing therapies in the pharmaceutical and biotechnology industry. Prior to joining Lakefront in July 2025, he held leadership roles at EQRx, BeiGene, Epizyme, and Pharmacyclics. He began his career at Genentech and received his M.D. from the University of Maryland. His expertise is expected to drive the clinical development of gamgertamib and other future programs.

Strategic Context

The appointment follows Lakefront's acquisition of Ouro Medicines' operational assets on June 4, 2026. The Ouro portfolio is now a cornerstone of Lakefront's R&D pipeline, focusing on areas with unmet medical needs. Hedrick's role will be pivotal in advancing these programs and leveraging his experience in drug development.

Leadership Background

Lakefront Biotherapeutics, formerly known as Galapagos, is a biotechnology company focused on identifying, acquiring, and advancing promising opportunities in oncology and immunology & inflammation. The company employs a modality-agnostic approach to asset selection and prioritizes programs with clear clinical proof-of-concept.